L-nucleoside analogues against cancer-causing viruses have potential in the prevention, delayed onset and treatment of viral associated cancers

Antiviral Chemistry and Chemotherapy, Supplement

Volumn 12, Issue 1, 2001, Pages 5-11

  Cheng, Y C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 5 FLUOROCYTIDINE; ANTIVIRUS AGENT; CLEVUDINE; DEOXYURIDINE DERIVATIVE; DIDANOSINE; ELVUCITABINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

BURKITT LYMPHOMA; CANCER; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; LIVER CELL CARCINOMA; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; STOMACH CARCINOMA; T CELL LYMPHOMA; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; WART VIRUS;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HUMANS; NEOPLASMS; NUCLEOSIDES; ONCOGENIC VIRUSES;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; RNA VIRUSES;

EID: 0034804684     PISSN: 13502816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2
3. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5methyl-β-L-arabinofuranosyl uracil
4. Use of novel β-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma
5. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
6. Biochemical pharmacology of (+)- and (-),2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents
7. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
8. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′- dideoxycytidine
9. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′- dideoxycytidine
10. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
11. Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers
12. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
13. A novel action of human apurinic/apyrimidinic endonuclease (APE1): Excision of L-configuration deoxyribonucleaside analogs from the 3′ termini of DNA
14. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent
15. Mitochondrial myopathy caused by long-term zidovudine therapy
16. A preliminary trial of lamivudine for chronic hepatitis B infection
17. Lamivudine as initial treatment for chronic hepatitis B in the United States
18. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
19. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5- fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro
20. Differential gene expression in tumor metastasis: Nm23
21. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
22. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus
23. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
24. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
25. Antimicrobial agents
26. Design of anti-HIV compounds: From nucleoside to nucleoside 5′-triphosphate analogs. Problems and perspectives
27. Unique inhibitory effect of 1-(2′-deoxy-2′-fluoro-β-L-arabinofuranosyl)5-methyluracil 5′-triphosphate on Epstein-Barr virus and human DNA polymerases
28. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity
29. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication
30. A one-year trial of lamivudine for chronic hepatitis B
31. Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′-didehydro-β-L-5-fluorocytidine in the duck hepatitis B virus infection model
32. Antiviral activity of β-L-2′,3′-dideoxy-2′,3′-didehydro-5- fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus
33. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
34. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
35. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro
36. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
37. Unique metabolism of a novel antiviral L-nucleoslde analog, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil: A substrate for both thymidine kinase and deoxycytidine kinase
38. Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-β-L-arabinofuranosyl) purine nucleosides
39. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
40. nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13
41. A new human nm23 homologue (nm23-H5) specifically expressed in testis germinal cells
42. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
43. Telomerase from human leukemia cells: Properties and its interaction with deoxynucleoside analogues
44. Molecular biology commentary mitochondrial toxicity of antiviral nucleoside analogs
45. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes
46. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection
47. Identification of a second human nm23 gene, nm23-H2
48. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines
49. Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells
50. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
51. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5- fluorocytidine